speb/financial-data huggingface dataset:
Financial ratios for ABEC.DE — annual report dated 2024-12-31
Total revenue: 350018000000
Gross profit: 203712000000
Operating income: 112390000000
Net income: 100118000000
Capital expenditures: 52535000000
Operating cash flow: 125299000000
Depreciation & amortization: 15311000000
Net tangible assets: 293199000000
Owner earnings: 62894000000
Return on net tangible assets (%): 21.450959928239865
Capex to operating income (%): 46.7434825162381
Buffett classification: The Good
Stock price: 190.30208333333334
P/E ratio: 10.505599538378048
Shares outstanding: 5527000000
Book value: 325084000000
P/B ratio: 3.235470261788748
Market cap (USD): 1051799614583.3334
Debt to equity: 0.06944051383642381
Current ratio: 1.8369313974102914
Quick ratio: 1.8369313974102914
Effective tax rate (%): 16.439510912657013
Interest coverage ratio: 419.36567164179104
COGS to revenue (%): 41.79956459382089
R&D to revenue (%): 14.092418104211784
SG&A to revenue (%): 11.998240090509631
Free cash flow (dilution-adjusted): 49979000000
Buyback yield (%): 5.915765620873422
Retained earnings: 245084000000
Receivables turnover: 6.687390141383263
Capitalized R&D asset: 92797090000
ROCI (R&D-adjusted, %): 25.767126900252634
Rosenberg metric: 0.6526955334932969
FCF margin (%): 14.278979938174608
Revenue growth (%): 13.866243322901553
Rule of 40 score: 28.14522326107616
Financial ratios for ABEC.DE — quarterly report dated 2025-03-31
Total revenue: 90234000000
Gross profit: 53873000000
Operating income: 30606000000
Net income: 34540000000
Capital expenditures: 17197000000
Operating cash flow: 36150000000
Depreciation & amortization: 4487000000
Net tangible assets: 313094000000
Owner earnings: 21830000000
Return on net tangible assets (%): 6.972346962892933
Capex to operating income (%): 56.18832908580017
Buffett classification: The Good
Stock price: 155.0108695652174
P/E ratio: 6.20110796241283
Shares outstanding: 5527000000
Book value: 345267000000
P/B ratio: 2.481398674321486
Market cap (USD): 856745076086.9565
Debt to equity: 0.06824863076981003
Current ratio: 1.7680843171056364
Quick ratio: 1.7680843171056364
Effective tax rate (%): 17.3466701763622
Interest coverage ratio: 900.1764705882352
COGS to revenue (%): 40.29634062548485
R&D to revenue (%): 15.023162001019571
SG&A to revenue (%): 10.762018751246758
Free cash flow (dilution-adjusted): 13437000000
Buyback yield (%): 1.758749530119348
Retained earnings: 262628000000
Receivables turnover: 1.769294117647059
Capitalized R&D asset: 13556000000
ROCI (R&D-adjusted, %): 9.978788885644574
FCF margin (%): 14.891282665070815
Rule of 40 score: 14.891282665070815
Financial ratios for ABEC.DE — quarterly report dated 2025-06-30
Total revenue: 96428000000
Gross profit: 57389000000
Operating income: 31271000000
Net income: 28196000000
Capital expenditures: 22446000000
Operating cash flow: 27747000000
Depreciation & amortization: 4998000000
Net tangible assets: 330581000000
Owner earnings: 10748000000
Return on net tangible assets (%): 3.251245534377354
Capex to operating income (%): 71.77896453583192
Buffett classification: The Good
Stock price: 176.8470588235294
P/E ratio: 15.580108615749284
Shares outstanding: 5527000000
Book value: 362916000000
P/B ratio: 2.693278042625971
Market cap (USD): 977433694117.6471
Debt to equity: 0.09798135105644282
Current ratio: 1.9037452754552744
Quick ratio: 1.9037452754552744
Effective tax rate (%): 16.906845843279402
Interest coverage ratio: 119.81226053639847
COGS to revenue (%): 40.48512880076326
R&D to revenue (%): 14.31949226365786
SG&A to revenue (%): 12.766001576305639
Free cash flow (dilution-adjusted): -697000000
Buyback yield (%): 1.354362969034975
Retained earnings: 275760000000
Receivables turnover: 1.7517076006394419
Capitalized R&D asset: 22890520000
ROCI (R&D-adjusted, %): 8.216387690473677
Rosenberg metric: 0.25936854529359693
FCF margin (%): -0.7228190981872485
Revenue growth (%): 6.864374847618413
Rule of 40 score: 6.141555749431165
Financial ratios for ABEC.DE — quarterly report dated 2025-09-30
Total revenue: 102346000000
Gross profit: 60977000000
Operating income: 31228000000
Net income: 34979000000
Capital expenditures: 23953000000
Operating cash flow: 48414000000
Depreciation & amortization: 5611000000
Net tangible assets: 353598000000
Owner earnings: 16637000000
Return on net tangible assets (%): 4.7050605489850055
Capex to operating income (%): 76.70359933393108
Buffett classification: The Gruesome
Stock price: 240.75294117647059
P/E ratio: 13.617576686100936
Shares outstanding: 5527000000
Book value: 386867000000
P/B ratio: 3.4395322058546034
Market cap (USD): 1330641505882.353
Debt to equity: 0.08714364368116174
Current ratio: 1.7473329984932195
Quick ratio: 1.7473329984932195
Effective tax rate (%): 20.478777820719756
Interest coverage ratio: 218.37762237762237
COGS to revenue (%): 40.420729681668064
R&D to revenue (%): 14.803705078850173
SG&A to revenue (%): 14.263381079866337
Free cash flow (dilution-adjusted): 18093000000
Buyback yield (%): 0.8946060939310935
Retained earnings: 297226000000
Receivables turnover: 1.7908938195562398
Capitalized R&D asset: 28875840000
ROCI (R&D-adjusted, %): 6.914489077065203
Rosenberg metric: 0.2598493626882966
FCF margin (%): 17.678267836554433
Revenue growth (%): 6.137221553905505
Rule of 40 score: 23.815489390459938
Financial ratios for ABEC.DE — quarterly report dated 2025-12-31
Total revenue: 113829000000
Gross profit: 68062000000
Operating income: 35934000000
Net income: 34455000000
Capital expenditures: 27851000000
Operating cash flow: 52402000000
Depreciation & amortization: 6040000000
Net tangible assets: 381885000000
Owner earnings: 12644000000
Return on net tangible assets (%): 3.3109443942548147
Capex to operating income (%): 77.50598319140647
Buffett classification: The Gruesome
Stock price: 314
P/E ratio: 13.130649920556857
Shares outstanding: 5527000000
Book value: 415265000000
P/B ratio: 4.179206049149339
Market cap (USD): 1735478000000
Debt to equity: 0.14277870757227312
Current ratio: 2.005333592875566
Quick ratio: 2.005333592875566
Effective tax rate (%): 11.918091878211518
Interest coverage ratio: 120.58389261744966
COGS to revenue (%): 40.2068014302155
R&D to revenue (%): 16.315701622609353
SG&A to revenue (%): 11.909091707737044
Free cash flow (dilution-adjusted): 17480000000
Buyback yield (%): 0.31685794922205873
Retained earnings: 324055000000
Receivables turnover: 1.8100849155614922
Capitalized R&D asset: 33279810000
ROCI (R&D-adjusted, %): 7.352828233394757
Rosenberg metric: 0.4676258992805755
FCF margin (%): 15.356367885161076
Revenue growth (%): 11.219783870400407
Rule of 40 score: 26.576151755561483
Financial ratios for ABEC.DE — annual report dated 2025-12-31
Total revenue: 402836000000
Gross profit: 240301000000
Operating income: 129039000000
Net income: 132170000000
Capital expenditures: 91447000000
Operating cash flow: 164713000000
Depreciation & amortization: 21136000000
Net tangible assets: 381885000000
Owner earnings: 61859000000
Return on net tangible assets (%): 16.198331958573917
Capex to operating income (%): 70.86772216151707
Buffett classification: The Good
Stock price: 314
P/E ratio: 13.130649920556857
Shares outstanding: 5527000000
Book value: 415265000000
P/B ratio: 4.179206049149339
Market cap (USD): 1735478000000
Debt to equity: 0.14277870757227312
Current ratio: 2.005333592875566
Quick ratio: 2.005333592875566
Effective tax rate (%): 16.783146336242176
Interest coverage ratio: 175.32472826086956
COGS to revenue (%): 40.34768491396002
R&D to revenue (%): 15.164235569810048
SG&A to revenue (%): 12.455440923849904
Free cash flow (dilution-adjusted): 48313000000
Buyback yield (%): 2.6337988727025063
Retained earnings: 324055000000
Receivables turnover: 6.405813694622014
Capitalized R&D asset: 109126330000
ROCI (R&D-adjusted, %): 22.96625971802711
Rosenberg metric: 0.7417791833921259
FCF margin (%): 11.993218083785957
Revenue growth (%): 15.090081081544376
Rule of 40 score: 27.08329916533033
Financial ratios for ADYA.V — annual report dated 2021-12-31
Total revenue: 3867162.2047244096
Gross profit: 1817491.338582677
Operating income: -627196.8503937008
Net income: -586621.2598425196
Capital expenditures: 3510.236220472441
Operating cash flow: -54929.92125984252
Depreciation & amortization: 260925.1968503937
Net tangible assets: -1539859.0551181103
Owner earnings: -329206.2992125984
Buffett classification: The Gruesome
Stock price: 0.07874015748031496
Shares outstanding: 23613540
Book value: -1539084.2519685037
Market cap (USD): 1859333.8582677166
Debt to equity: -0.6738903438336633
Current ratio: 0.3652661759264427
Quick ratio: 0.35125754766319595
Interest coverage ratio: -6.7292388274055925
COGS to revenue (%): 53.002038565787934
R&D to revenue (%): 6.23501413883423
SG&A to revenue (%): 50.23437805418366
Free cash flow (dilution-adjusted): -58440.15748031496
Buyback yield (%): 0
Retained earnings: -6464792.1259842515
Inventory turnover: 76.82348601109669
Receivables turnover: 18.41567956923931
Capitalized R&D asset: 241118.11023622047
FCF margin (%): -1.511189714486767
Rule of 40 score: -1.511189714486767
Financial ratios for ADYA.V — annual report dated 2022-12-31
Total revenue: 3057260.2941176468
Gross profit: 1671131.6176470588
Operating income: -679988.9705882353
Net income: -740530.1470588235
Capital expenditures: 3180.882352941176
Operating cash flow: -25191.176470588234
Depreciation & amortization: 194274.26470588235
Net tangible assets: -2177763.2352941176
Owner earnings: -549436.7647058824
Buffett classification: The Gruesome
Stock price: 0.058823529411764705
Shares outstanding: 23613540
Book value: -2177763.2352941176
Market cap (USD): 1389031.7647058824
Debt to equity: -0.37022403585978325
Current ratio: 0.18989473947701144
Quick ratio: 0.18561642031826123
Interest coverage ratio: -10.229017343597913
COGS to revenue (%): 45.338915994087365
R&D to revenue (%): 7.253250098487833
SG&A to revenue (%): 63.29508782613422
Free cash flow (dilution-adjusted): -28372.05882352941
Buyback yield (%): 0
Retained earnings: -6777505.147058823
Inventory turnover: 114.89121160409556
Receivables turnover: 25.672544733819876
Capitalized R&D asset: 383299.86915238533
Rosenberg metric: -0.6070042635629129
FCF margin (%): -0.9280223498836184
Revenue growth (%): -20.94305508099265
Rule of 40 score: -21.87107743087627
Financial ratios for ADYA.V — annual report dated 2023-12-31
Total revenue: 1642759.8484848484
Gross profit: 882403.0303030303
Operating income: -613417.4242424242
Net income: -351625
Capital expenditures: 0
Operating cash flow: -189646.9696969697
Depreciation & amortization: 157077.2727272727
Net tangible assets: -2595381.0606060605
Owner earnings: -194547.7272727273
Buffett classification: The Gruesome
Stock price: 0.022727272727272724
Shares outstanding: 23613540
Book value: -2595381.0606060605
Market cap (USD): 536671.3636363635
Debt to equity: -0.2935445049086328
Current ratio: 0.12130920087161472
Quick ratio: 0.11823212141618332
Interest coverage ratio: -10.208285530579055
COGS to revenue (%): 46.28533007323688
R&D to revenue (%): 12.284205764228066
SG&A to revenue (%): 69.20933591521657
Free cash flow (dilution-adjusted): -189646.9696969697
Buyback yield (%): 0
Retained earnings: -7334509.090909091
Inventory turnover: 82.8863655132546
Receivables turnover: 16.16274978943524
Capitalized R&D asset: 429941.9690250115
Rosenberg metric: -3.556825127537474
FCF margin (%): -11.544412281069874
Revenue growth (%): -46.26692886943197
Rule of 40 score: -57.811341150501846
Financial ratios for ADYA.V — quarterly report dated 2024-09-30
Total revenue: 246725.18518518517
Gross profit: 33474.81481481481
Operating income: -258680.74074074073
Net income: -274123.7037037037
Capital expenditures: 0
Operating cash flow: 0
Depreciation & amortization: 267.4074074074074
Net tangible assets: -3113052.5925925924
Owner earnings: -273856.2962962963
Buffett classification: The Gruesome
Stock price: 0.037037037037037035
Shares outstanding: 23613540
Book value: -3113052.5925925924
Market cap (USD): 874575.5555555555
Debt to equity: -0.2575652194190245
Current ratio: 0.08906111202972763
Quick ratio: 0.08648766141494925
Interest coverage ratio: -16.18553021876159
COGS to revenue (%): 86.54073057743058
R&D to revenue (%): 19.415213808135608
SG&A to revenue (%): 98.88975288144854
Free cash flow (dilution-adjusted): 0
Buyback yield (%): 0
Retained earnings: -7746866.666666666
Inventory turnover: 24.2736
Receivables turnover: 2.360404220790725
Capitalized R&D asset: 47902.22222222222
FCF margin (%): 0
Rule of 40 score: 0
Financial ratios for ADYA.V — quarterly report dated 2024-12-31
Total revenue: 539758.7412587412
Gross profit: 421696.5034965035
Operating income: 194708.39160839163
Net income: 127308.39160839161
Capital expenditures: 0
Operating cash flow: -421934.9650349651
Depreciation & amortization: 86644.75524475524
Net tangible assets: -2811587.4125874126
Owner earnings: 213953.14685314684
Return on net tangible assets (%): -7.609692158077087
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 0.02097902097902098
P/E ratio: 0.9728128381607352
Shares outstanding: 23613540
Book value: -2811587.4125874126
Market cap (USD): 495388.9510489511
Debt to equity: -0.8286800130329779
Current ratio: 0.3955837101469869
Quick ratio: 0.3901463441040293
Effective tax rate (%): 0
Interest coverage ratio: 2.864153971176694
COGS to revenue (%): 21.873149749629142
R&D to revenue (%): 3.3160373386193007
SG&A to revenue (%): 22.685478490130922
Free cash flow (dilution-adjusted): -421934.9650349651
Buyback yield (%): 0
Retained earnings: -7186167.132867133
Inventory turnover: 13.131290347670529
Receivables turnover: 1.376311932298409
Capitalized R&D asset: 49993.09028749029
Rosenberg metric: 8.10446093462423
FCF margin (%): -78.17102953274903
Revenue growth (%): 118.76921111787316
Rule of 40 score: 40.598181585124124
Financial ratios for ADYA.V — annual report dated 2024-12-31
Total revenue: 1252004.195804196
Gross profit: 706872.027972028
Operating income: -308693.00699300703
Net income: -415851.048951049
Capital expenditures: 0
Operating cash flow: -353558.7412587413
Depreciation & amortization: 108395.1048951049
Net tangible assets: -2811587.4125874126
Owner earnings: -307455.9440559441
Buffett classification: The Gruesome
Stock price: 0.02097902097902098
Shares outstanding: 23613540
Book value: -2811587.4125874126
Market cap (USD): 495388.9510489511
Debt to equity: -0.8286800130329779
Current ratio: 0.3955837101469869
Quick ratio: 0.3901463441040293
Interest coverage ratio: -2.8251945624904002
COGS to revenue (%): 43.54076205647336
R&D to revenue (%): 11.247420918404393
SG&A to revenue (%): 61.20999840256126
Free cash flow (dilution-adjusted): -353558.7412587413
Buyback yield (%): 0
Retained earnings: -7186167.132867133
Inventory turnover: 60.63148479427549
Receivables turnover: 3.1924417008134607
Capitalized R&D asset: 349201.9244652407
Rosenberg metric: -0.869826572502489
FCF margin (%): -28.239421436734162
Revenue growth (%): -23.786535386840292
Rule of 40 score: -52.025956823574454
Financial ratios for ADYA.V — quarterly report dated 2025-03-31
Total revenue: 165188.1118881119
Gross profit: 64461.53846153846
Operating income: -123366.43356643357
Net income: -160437.06293706293
Capital expenditures: 0
Operating cash flow: -164018.18181818182
Depreciation & amortization: 26169.23076923077
Net tangible assets: -2972024.475524476
Owner earnings: -134267.83216783215
Buffett classification: The Gruesome
Stock price: 0.1258741258741259
Shares outstanding: 23613540
Book value: -2972024.475524476
Market cap (USD): 2972333.706293707
Debt to equity: -0.8304659181951978
Current ratio: 0.39399873550391024
Quick ratio: 0.38861868653651127
Interest coverage ratio: -3.2706205157678117
COGS to revenue (%): 60.97731342525369
R&D to revenue (%): 5.683285425812488
SG&A to revenue (%): 92.18013792285973
Free cash flow (dilution-adjusted): -164018.18181818182
Buyback yield (%): 0
Retained earnings: -7346604.195804196
Inventory turnover: 11.360517390961434
Receivables turnover: 0.4220412144947526
Capitalized R&D asset: 37187.90815850816
Rosenberg metric: -19.958820082047275
FCF margin (%): -99.29175891863059
Revenue growth (%): -69.39593576513722
Rule of 40 score: -168.6876946837678
Financial ratios for ADYA.V — quarterly report dated 2025-06-30
Total revenue: 1820299.9999999998
Gross profit: 258675.1824817518
Operating income: 27118.97810218978
Net income: 12086.861313868612
Capital expenditures: 0
Operating cash flow: -243221.89781021897
Depreciation & amortization: 27137.22627737226
Net tangible assets: -3090099.2700729924
Owner earnings: 39224.087591240874
Return on net tangible assets (%): -1.2693471685883524
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 0.18248175182481752
P/E ratio: 89.12653239929949
Shares outstanding: 23613540
Book value: -3090099.270072993
Market cap (USD): 4309040.145985401
Debt to equity: -0.8957163873506059
Current ratio: 0.687545884907223
Quick ratio: 0.6840535958099246
Effective tax rate (%): 0
Interest coverage ratio: 1.4982860829939104
COGS to revenue (%): 85.78942028886712
R&D to revenue (%): 0.5212504075088289
SG&A to revenue (%): 10.727837835345182
Free cash flow (dilution-adjusted): -243221.89781021897
Buyback yield (%): 0
Retained earnings: -7656266.423357664
Inventory turnover: 171.40089729210064
Receivables turnover: 1.173237892716341
Capitalized R&D asset: 21684.894594456637
Rosenberg metric: 20.68718889749758
FCF margin (%): -13.361638071209086
Revenue growth (%): 1001.9558121912291
Rule of 40 score: 988.59417412002
Financial ratios for ADYA.V — quarterly report dated 2025-09-30
Total revenue: 1723851.0791366908
Gross profit: -230057.55395683454
Operating income: -496935.2517985612
Net income: -515897.84172661876
Capital expenditures: 0
Operating cash flow: -310542.4460431655
Depreciation & amortization: 27005.035971223024
Net tangible assets: -3561535.2517985613
Owner earnings: -488892.80575539573
Buffett classification: The Gruesome
Stock price: 0.4244604316546763
Shares outstanding: 23613540
Book value: -3561535.2517985613
Market cap (USD): 10023013.381294964
Debt to equity: -0.8575398128767523
Current ratio: 0.41140619318804317
Quick ratio: 0.40595791970409445
Interest coverage ratio: -25.93646740762992
COGS to revenue (%): 113.36542366034222
R&D to revenue (%): 0.868141558573263
SG&A to revenue (%): 13.046787913793484
Free cash flow (dilution-adjusted): -310542.4460431655
Buyback yield (%): 0
Retained earnings: -8062002.158273382
Inventory turnover: 217.62610158628428
Receivables turnover: 4.307752740713575
Capitalized R&D asset: 24420.719731457953
Rosenberg metric: -51.50887367650307
FCF margin (%): -18.01445900992132
Revenue growth (%): -5.298517874158598
Rule of 40 score: -23.31297688407992
Financial ratios for AGA.V — quarterly report dated 2025-01-31
Total revenue: 0
Gross profit: 0
Operating income: -867151.0344827586
Net income: -557424.827586207
Capital expenditures: 0
Operating cash flow: -264651.0344827586
Depreciation & amortization: 0
Net tangible assets: 7721288.275862069
Owner earnings: -557424.827586207
Return on net tangible assets (%): -7.21932412922339
Buffett classification: The Gruesome
Stock price: 0.39999999999999997
Shares outstanding: 208658355
Book value: 7721288.27586207
P/B ratio: 10.809509892399587
Market cap (USD): 83463342
Debt to equity: 0
Current ratio: 0.7640437872187683
Quick ratio: 0.7640437872187683
Free cash flow (dilution-adjusted): -223286.2068965517
Buyback yield (%): 0
Retained earnings: -7449053.103448276
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -11.206462368432897
Rule of 40 score: 0
Financial ratios for AGA.V — quarterly report dated 2025-04-30
Total revenue: 0
Gross profit: -497.8260869565218
Operating income: -1882713.043478261
Net income: -2002418.8405797102
Capital expenditures: 5597.826086956522
Operating cash flow: -1600995.652173913
Depreciation & amortization: 497.8260869565218
Net tangible assets: 13460846.376811596
Owner earnings: -2007518.8405797102
Return on net tangible assets (%): -14.913763847999736
Buffett classification: The Gruesome
Stock price: 0.47826086956521746
Shares outstanding: 208658355
Book value: 13460846.376811596
P/B ratio: 7.413584815606917
Market cap (USD): 99793126.30434784
Debt to equity: 0
Current ratio: 9.862361516695502
Quick ratio: 9.862361516695502
Free cash flow (dilution-adjusted): -2191542.7536231885
Buyback yield (%): 0
Retained earnings: -9829322.463768117
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -13.955597447481145
Rule of 40 score: 0
Financial ratios for AGA.V — annual report dated 2025-07-31
Total revenue: 0
Gross profit: -1865.217391304348
Operating income: -7442271.7391304355
Net income: -7341062.31884058
Capital expenditures: 7771.014492753624
Operating cash flow: -6185360.869565218
Depreciation & amortization: 1865.217391304348
Net tangible assets: 9991686.231884059
Owner earnings: -7346968.115942029
Return on net tangible assets (%): -73.53081297226309
Buffett classification: The Gruesome
Stock price: 0.6811594202898551
Shares outstanding: 208658355
Book value: 9991686.231884059
P/B ratio: 14.224786570748273
Market cap (USD): 142129604.13043478
Debt to equity: 0
Current ratio: 1.8987264365721026
Quick ratio: 1.8987264365721026
Free cash flow (dilution-adjusted): -7543368.840579711
Buyback yield (%): 0
Retained earnings: -13529150.000000002
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -74.4846421956457
Rule of 40 score: 0
Financial ratios for AGA.V — quarterly report dated 2025-07-31
Total revenue: 0
Gross profit: -1367.3913043478262
Operating income: -3549768.8405797104
Net income: -3699827.5362318843
Capital expenditures: 2173.1884057971015
Operating cash flow: -1887786.231884058
Depreciation & amortization: 1367.3913043478262
Net tangible assets: 9991686.231884059
Owner earnings: -3700633.3333333335
Return on net tangible assets (%): -37.03712514034312
Buffett classification: The Gruesome
Stock price: 0.6811594202898551
Shares outstanding: 208658355
Book value: 9991686.231884059
P/B ratio: 14.224786570748273
Market cap (USD): 142129604.13043478
Debt to equity: 0
Current ratio: 1.8987264365721026
Quick ratio: 1.8987264365721026
Free cash flow (dilution-adjusted): -2463536.9565217393
Buyback yield (%): 0
Retained earnings: -13529150.000000002
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -35.5272249167732
Rule of 40 score: 0
Financial ratios for AGA.V — quarterly report dated 2025-10-31
Total revenue: 0
Gross profit: -686.4285714285714
Operating income: -6061705
Net income: -5821032.142857144
Capital expenditures: 56689.28571428572
Operating cash flow: -5641015
Depreciation & amortization: 686.4285714285714
Net tangible assets: 72178665.71428572
Owner earnings: -5877035.000000001
Return on net tangible assets (%): -8.142343643846008
Buffett classification: The Gruesome
Stock price: 0.5071428571428571
Shares outstanding: 208658355
Book value: 72178665.71428572
P/B ratio: 1.4660785603921822
Market cap (USD): 105819594.32142857
Debt to equity: 0
Current ratio: 16.835672736469398
Quick ratio: 16.835672736469398
Free cash flow (dilution-adjusted): -7921402.857142858
Buyback yield (%): 0
Retained earnings: -19156908.57142857
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -8.39819486826598
Rule of 40 score: 0
Financial ratios for AGA.V — quarterly report dated 2026-01-31
Total revenue: 0
Gross profit: -9668.148148148148
Operating income: -4276300.740740741
Net income: -4468440.740740741
Capital expenditures: 319011.11111111107
Operating cash flow: -3861093.333333333
Depreciation & amortization: 9668.148148148148
Net tangible assets: 96128918.51851851
Owner earnings: -4777783.703703703
Return on net tangible assets (%): -4.970183559053876
Buffett classification: The Gruesome
Stock price: 0.6666666666666666
Shares outstanding: 208658355
Book value: 96128918.51851852
P/B ratio: 1.4470730779437857
Market cap (USD): 139105570
Debt to equity: 0
Current ratio: 62.960075467517655
Quick ratio: 62.960075467517655
Free cash flow (dilution-adjusted): -5654042.222222222
Buyback yield (%): 0
Retained earnings: -24152118.51851852
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -4.4485060340265274
Rule of 40 score: 0
Financial ratios for ALBI.PA — annual report dated 2021-12-31
Total revenue: 453237500
Gross profit: 231435227.27272728
Operating income: 16438636.363636363
Net income: 14625000
Capital expenditures: 28670454.545454547
Operating cash flow: 39311363.63636363
Depreciation & amortization: 18255681.818181816
Net tangible assets: 167168181.8181818
Owner earnings: 4210227.27272727
Return on net tangible assets (%): 2.518557794273593
Capex to operating income (%): 174.40895893819993
Buffett classification: The Gruesome
Stock price: 4.25
P/E ratio: 10.938721777777777
Shares outstanding: 37642072
Book value: 179526136.36363637
P/B ratio: 0.8911170776602546
Market cap (USD): 159978806
Debt to equity: 0.8067703487084052
Quick ratio: -0.5349581367191512
Effective tax rate (%): 6.934702436907947
Interest coverage ratio: 4.126069594980034
COGS to revenue (%): 48.93731713004169
SG&A to revenue (%): 24.472670108236454
Free cash flow (dilution-adjusted): 10640909.090909092
Buyback yield (%): 0
Retained earnings: 14625000
Inventory turnover: 1.972153459094078
Receivables turnover: 5.913868007057811
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 6.683020803015814
FCF margin (%): 2.3477556669315955
Rule of 40 score: 2.3477556669315955
Financial ratios for ALBI.PA — annual report dated 2022-12-31
Total revenue: 489592553.1914894
Gross profit: 253827659.5744681
Operating income: 37439361.702127665
Net income: 23955319.14893617
Capital expenditures: 49404255.319148935
Operating cash flow: 40712765.95744681
Depreciation & amortization: 24268085.10638298
Net tangible assets: 184356382.9787234
Owner earnings: -1180851.063829787
Return on net tangible assets (%): -0.6405262702328398
Capex to operating income (%): 131.95805984144573
Buffett classification: The Gruesome
Stock price: 4.75531914893617
P/E ratio: 7.472247172928324
Shares outstanding: 37642072
Book value: 196624468.08510637
P/B ratio: 0.9103651622327906
Market cap (USD): 179000065.78723404
Debt to equity: 0.7216965053807074
Current ratio: 1.3801714478422158
Quick ratio: 0.6859164735702707
Effective tax rate (%): 11.350393700787402
Interest coverage ratio: 9.896794150731159
COGS to revenue (%): 48.1553267263052
SG&A to revenue (%): 23.641021518109934
Free cash flow (dilution-adjusted): -8691489.361702127
Buyback yield (%): 0
Retained earnings: 23955319.14893617
Inventory turnover: 1.736336143407816
Receivables turnover: 6.516070113835872
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 12.44910592688233
FCF margin (%): -1.7752495018654242
Revenue growth (%): 8.021192684076096
Rule of 40 score: 6.245943182210672
Financial ratios for ALBI.PA — annual report dated 2023-12-31
Total revenue: 456944444.4444444
Gross profit: 223471111.1111111
Operating income: 19255555.555555556
Net income: 10746666.666666666
Capital expenditures: 90788888.88888888
Operating cash flow: 37437777.777777776
Depreciation & amortization: 23124444.444444444
Net tangible assets: 201144444.44444445
Owner earnings: -56917777.77777777
Return on net tangible assets (%): -28.29696735347732
Capex to operating income (%): 471.49451817657234
Buffett classification: The Gruesome
Stock price: 4.044444444444444
P/E ratio: 14.166371182795698
Shares outstanding: 37642072
Book value: 214684444.44444442
P/B ratio: 0.7091397300430606
Market cap (USD): 152241268.97777778
Debt to equity: 0.9272472259026169
Current ratio: 1.4715496440704419
Quick ratio: 0.7812443729517544
Effective tax rate (%): 9.566111838414065
Interest coverage ratio: 3.2140207715133533
COGS to revenue (%): 51.094468085106385
Free cash flow (dilution-adjusted): -53351111.11111111
Buyback yield (%): 0
Retained earnings: 10746666.666666666
Inventory turnover: 1.827039622986027
Receivables turnover: 7.211369853405345
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 4.742501074109448
FCF margin (%): -11.675623100303953
Revenue growth (%): -6.668424291632487
Rule of 40 score: -18.344047391936442
Financial ratios for ALBI.PA — quarterly report dated 2024-12-31
Capital expenditures: 0
Net tangible assets: 210478125
Buffett classification: The Gruesome
Stock price: 2.4791666666666665
Shares outstanding: 37642072
Book value: 223328125
P/B ratio: 0.4178648352806735
Market cap (USD): 93320970.16666666
Debt to equity: 1.1847384500571376
Current ratio: 1.7916960801477357
Quick ratio: 1.0710046139162943
Buyback yield (%): 0
Retained earnings: -651041.6666666667
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for ALBI.PA — annual report dated 2024-12-31
Total revenue: 407509375
Gross profit: 207646875
Operating income: 4740625
Net income: -651041.6666666667
Capital expenditures: 67332291.66666667
Operating cash flow: 22789583.333333336
Depreciation & amortization: 25845833.333333336
Net tangible assets: 210478125
Owner earnings: -42137500
Return on net tangible assets (%): -20.01989517913085
Capex to operating income (%): 1420.3252032520327
Buffett classification: The Gruesome
Stock price: 2.4791666666666665
Shares outstanding: 37642072
Book value: 223328125
P/B ratio: 0.4178648352806735
Market cap (USD): 93320970.16666666
Debt to equity: 1.1847384500571376
Current ratio: 1.7916960801477357
Quick ratio: 1.0710046139162943
Interest coverage ratio: 0.8862706913339824
COGS to revenue (%): 49.044883936719245
Free cash flow (dilution-adjusted): -44542708.333333336
Buyback yield (%): 0
Retained earnings: -651041.6666666667
Inventory turnover: 1.5034909689299847
Receivables turnover: 6.492772144125603
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 0.9667613388932909
FCF margin (%): -10.93047450339844
Revenue growth (%): -10.81861702127659
Rule of 40 score: -21.74909152467503
Financial ratios for BIO — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 755.57
Shares outstanding: 21700560
Market cap (USD): 16396292119.2
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for BIO — annual report dated 2022-12-31
Total revenue: 2802200000
Gross profit: 1567300000
Operating income: 475100000
Net income: -3627500000
Capital expenditures: 112600000
Operating cash flow: 194400000
Depreciation & amortization: 137300000
Net tangible assets: 8876652000
Owner earnings: -3602800000
Return on net tangible assets (%): -40.58737460925583
Capex to operating income (%): 23.700273626604925
Buffett classification: The Great
Stock price: 420.49
Shares outstanding: 21700560
Book value: 9615252000
P/B ratio: 0.9489994099374619
Market cap (USD): 9124868474.4
Debt to equity: 0.14436418307081292
Current ratio: 5.5528953346884515
Quick ratio: 4.288070503667964
Interest coverage ratio: 12.469816272965879
COGS to revenue (%): 44.06894582827778
R&D to revenue (%): 9.167796731139818
SG&A to revenue (%): 29.5410748697452
Free cash flow (dilution-adjusted): 19200000
Buyback yield (%): 2.3638696886990824
Retained earnings: 9898203000
Inventory turnover: 1.716769820218096
Receivables turnover: 5.665072931091995
Capitalized R&D asset: 256900000
ROCI (R&D-adjusted, %): 4.900482375675816
FCF margin (%): 0.6851759331953465
Rule of 40 score: 0.6851759331953465
Financial ratios for BIO — annual report dated 2023-12-31
Total revenue: 2671200000
Gross profit: 1426900000
Operating income: 337800000
Net income: -637300000
Capital expenditures: 156500000
Operating cash flow: 374900000
Depreciation & amortization: 145900000
Net tangible assets: 8007100000
Owner earnings: -647900000
Return on net tangible assets (%): -8.091568732749685
Capex to operating income (%): 46.32918886915334
Buffett classification: The Good
Stock price: 322.89
Shares outstanding: 21700560
Book value: 8741200000
P/B ratio: 0.8015940395369057
Market cap (USD): 7006893818.4
Debt to equity: 0.16079028051068503
Current ratio: 5.830719204284621
Quick ratio: 4.337796480489671
Interest coverage ratio: 6.838056680161944
COGS to revenue (%): 46.582060497154835
R&D to revenue (%): 9.261755016471998
SG&A to revenue (%): 31.510182689427975
Free cash flow (dilution-adjusted): 156900000
Buyback yield (%): 6.118260260691265
Retained earnings: 9260600000
Inventory turnover: 1.594234465086483
Receivables turnover: 5.462576687116565
Capitalized R&D asset: 419523000
ROCI (R&D-adjusted, %): 3.4200233965350266
Rosenberg metric: -0.546516154145582
FCF margin (%): 5.873764600179694
Revenue growth (%): -4.6748982941974155
Rule of 40 score: 1.1988663059822784
Financial ratios for BIO — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 334.58
Shares outstanding: 21700560
Market cap (USD): 7260573364.799999
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for BIO — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 328.51
Shares outstanding: 21700560
Market cap (USD): 7128850965.599999
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for BIO — annual report dated 2024-12-31
Total revenue: 2566500000
Gross profit: 1378900000
Operating income: 269000000
Net income: -1844200000
Capital expenditures: 165500000
Operating cash flow: 455200000
Depreciation & amortization: 151600000
Net tangible assets: 5865200000
Owner earnings: -1858100000
Return on net tangible assets (%): -31.680079110686766
Capex to operating income (%): 61.52416356877324
Buffett classification: The Good
Stock price: 328.51
Shares outstanding: 21700560
Book value: 6569300000
P/B ratio: 1.0851766498104822
Market cap (USD): 7128850965.599999
Debt to equity: 0.20926126071270912
Current ratio: 6.477768277041471
Quick ratio: 4.853142368533561
Interest coverage ratio: 5.5010224948875255
COGS to revenue (%): 46.27313461913111
R&D to revenue (%): 11.529320085719853
SG&A to revenue (%): 31.716345217221896
Free cash flow (dilution-adjusted): 203900000
Buyback yield (%): 2.856000230366213
Retained earnings: 7416400000
Inventory turnover: 1.5626315789473684
Receivables turnover: 5.67182320441989
Capitalized R&D asset: 546435000
ROCI (R&D-adjusted, %): 3.157630354623598
Rosenberg metric: -0.19401778496362165
FCF margin (%): 7.944671731930645
Revenue growth (%): -3.919586702605571
Rule of 40 score: 4.025085029325074
Financial ratios for BIO — quarterly report dated 2025-03-31
Total revenue: 585400000
Gross profit: 306000000
Operating income: 23700000
Net income: 64000000
Capital expenditures: 34400000
Operating cash flow: 129900000
Depreciation & amortization: 38100000
Net tangible assets: 5968700000
Owner earnings: 67700000
Return on net tangible assets (%): 1.1342503392698577
Capex to operating income (%): 145.1476793248945
Buffett classification: The Gruesome
Stock price: 243.56
P/E ratio: 20.6460484125
Shares outstanding: 21700560
Book value: 6679400000
P/B ratio: 0.7912968819953887
Market cap (USD): 5285388393.6
Debt to equity: 0.2050333862322963
Current ratio: 5.994078168180024
Quick ratio: 4.434465061192262
Effective tax rate (%): 23.26139088729017
Interest coverage ratio: 1.975
COGS to revenue (%): 47.72804919713017
R&D to revenue (%): 12.55551759480697
SG&A to revenue (%): 35.667919371370004
Free cash flow (dilution-adjusted): 80200000
Buyback yield (%): 1.9279567065192262
Retained earnings: 7480400000
Inventory turnover: 0.3536261232755347
Receivables turnover: 1.378384742170944
Capitalized R&D asset: 73500000
ROCI (R&D-adjusted, %): 0.7994457762431547
FCF margin (%): 13.700034164673728
Rule of 40 score: 13.700034164673728
Financial ratios for BIO — quarterly report dated 2025-06-30
Total revenue: 651600000
Gross profit: 345300000
Operating income: 77100000
Net income: 317800000
Capital expenditures: 45600000
Operating cash flow: 116500000
Depreciation & amortization: 40600000
Net tangible assets: 6150200000
Owner earnings: 312800000
Return on net tangible assets (%): 5.086013462976814
Capex to operating income (%): 59.143968871595334
Buffett classification: The Good
Stock price: 241.32
P/E ratio: 13.716027080146674
Shares outstanding: 21700560
Book value: 7128700000
P/B ratio: 0.7346050667302594
Market cap (USD): 5236779139.2
Debt to equity: 0.19730105068245263
Current ratio: 5.121333576243396
Quick ratio: 3.6660593915102933
Effective tax rate (%): 23.23671497584541
Interest coverage ratio: 6.119047619047619
COGS to revenue (%): 47.0073664825046
R&D to revenue (%): 9.284837323511356
SG&A to revenue (%): 31.87538367096378
Free cash flow (dilution-adjusted): 58900000
Buyback yield (%): 2.677218119636372
Retained earnings: 7798200000
Inventory turnover: 0.3834501752628943
Receivables turnover: 1.3866780165992765
Capitalized R&D asset: 109745000
ROCI (R&D-adjusted, %): 0.9507299870570458
Rosenberg metric: 0.5346938775510204
FCF margin (%): 9.039287906691222
Revenue growth (%): 11.308507003758114
Rule of 40 score: 20.347794910449338
Financial ratios for BIO — quarterly report dated 2025-09-30
Total revenue: 653000000
Gross profit: 343400000
Operating income: 63900000
Net income: -341900000
Capital expenditures: 31700000
Operating cash flow: 120900000
Depreciation & amortization: 44200000
Net tangible assets: 5769700000
Owner earnings: -329400000
Return on net tangible assets (%): -5.709135656966566
Capex to operating income (%): 49.60876369327074
Buffett classification: The Good
Stock price: 280.39
P/E ratio: 152.49674231578948
Shares outstanding: 21700560
Book value: 6736800000
P/B ratio: 0.9031914289276808
Market cap (USD): 6084620018.4
Debt to equity: 0.20711613822586392
Current ratio: 5.441317250622248
Quick ratio: 3.94179590273789
Interest coverage ratio: 5.195121951219512
COGS to revenue (%): 47.411944869831544
R&D to revenue (%): 10.918836140888208
SG&A to revenue (%): 31.669218989280246
Free cash flow (dilution-adjusted): 74300000
Buyback yield (%): 0.8776225933339706
Retained earnings: 7456300000
Inventory turnover: 0.3953013278855976
Receivables turnover: 1.4052076608564665
Capitalized R&D asset: 136090000
ROCI (R&D-adjusted, %): 0.7171353824859286
Rosenberg metric: -0.03140495867768595
FCF margin (%): 11.378254211332314
Revenue growth (%): 0.21485573971761818
Rule of 40 score: 11.593109951049932
Financial ratios for BIO — quarterly report dated 2025-12-31
Total revenue: 693200000
Gross profit: 345200000
Operating income: 53900000
Net income: 720000000
Capital expenditures: 45800000
Operating cash flow: 164900000
Depreciation & amortization: 42500000
Net tangible assets: 6699500000
Owner earnings: 716700000
Return on net tangible assets (%): 10.69781326964699
Capex to operating income (%): 84.97217068645641
Buffett classification: The Gruesome
Stock price: 302.99
P/E ratio: 8.652523587840506
Shares outstanding: 21700560
Book value: 7453600000
P/B ratio: 0.8821311412471825
Market cap (USD): 6575052674.400001
Debt to equity: 0.1859638295588709
Current ratio: 5.621276595744681
Quick ratio: 4.188588007736944
Effective tax rate (%): 22.51399052948773
Interest coverage ratio: 4.454545454545454
COGS to revenue (%): 50.201961915753024
R&D to revenue (%): 10.141373341027121
SG&A to revenue (%): 31.881130986728216
Free cash flow (dilution-adjusted): 103200000
Buyback yield (%): 0
Retained earnings: 8176300000
Inventory turnover: 0.46982584042122316
Receivables turnover: 1.5049934867564048
Capitalized R&D asset: 138036000
ROCI (R&D-adjusted, %): 0.5573241745195441
Rosenberg metric: 0.025245441795231416
FCF margin (%): 14.88747836122331
Revenue growth (%): 6.1562021439509955
Rule of 40 score: 21.043680505174308
Financial ratios for BIO — annual report dated 2025-12-31
Total revenue: 2583200000
Gross profit: 1339900000
Operating income: 218600000
Net income: 759900000
Capital expenditures: 157500000
Operating cash flow: 532200000
Depreciation & amortization: 165400000
Net tangible assets: 6699500000
Owner earnings: 767800000
Return on net tangible assets (%): 11.460556757967012
Capex to operating income (%): 72.04940530649588
Buffett classification: The Good
Stock price: 302.99
P/E ratio: 8.652523587840506
Shares outstanding: 21700560
Book value: 7453600000
P/B ratio: 0.8821311412471825
Market cap (USD): 6575052674.400001
Debt to equity: 0.1859638295588709
Current ratio: 5.621276595744681
Quick ratio: 4.188588007736944
Effective tax rate (%): 23.666499246609742
Interest coverage ratio: 4.461224489795918
COGS to revenue (%): 48.13022607618458
R&D to revenue (%): 10.66893775162589
SG&A to revenue (%): 32.68426757510065
Free cash flow (dilution-adjusted): 316600000
Buyback yield (%): 4.494260573006977
Retained earnings: 8176300000
Inventory turnover: 1.6785473201026055
Receivables turnover: 5.608336951801998
Capitalized R&D asset: 555495000
ROCI (R&D-adjusted, %): 2.0841586202662676
Rosenberg metric: -0.1318012842176411
FCF margin (%): 12.256116444719728
Revenue growth (%): 0.650691603350867
Rule of 40 score: 12.906808048070594
Financial ratios for BRO.V — annual report dated 2022-03-31
Total revenue: 0
Gross profit: -25345.6
Operating income: -1491299.2
Net income: -1495874.4
Capital expenditures: 2985492.8
Operating cash flow: -1195228.8
Depreciation & amortization: 25345.6
Net tangible assets: 11394688.8
Owner earnings: -4456021.6
Return on net tangible assets (%): -39.1061281111951
Buffett classification: The Gruesome
Stock price: 0.384
Shares outstanding: 206097077
Book value: 11394688.8
P/B ratio: 6.945453180608144
Market cap (USD): 79141277.568
Debt to equity: 0.1263215894057589
Current ratio: 1.3968591521215885
Quick ratio: 1.3968591521215885
Interest coverage ratio: -46.885585653562714
Free cash flow (dilution-adjusted): -4359901.6
Buyback yield (%): 0
Retained earnings: -22243206.4
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -12.962923428779488
Rule of 40 score: 0
Financial ratios for BRO.V — annual report dated 2023-03-31
Total revenue: 0
Gross profit: -19907.407407407405
Operating income: -1744425.9259259258
Net income: -2582493.333333333
Capital expenditures: 2147579.2592592593
Operating cash flow: -1280120
Depreciation & amortization: 19907.407407407405
Net tangible assets: 15256073.333333332
Owner earnings: -4710165.185185185
Return on net tangible assets (%): -30.87403345717958
Buffett classification: The Gruesome
Stock price: 0.437037037037037
Shares outstanding: 206097077
Book value: 15256073.333333332
P/B ratio: 5.904013038353299
Market cap (USD): 90072055.87407407
Debt to equity: 0.07719291294750423
Current ratio: 3.7548302781734413
Quick ratio: 3.7548302781734413
Interest coverage ratio: -14.42018602543613
Free cash flow (dilution-adjusted): -3972332.5925925924
Buyback yield (%): 0
Retained earnings: -22705919.259259257
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -11.37084115519509
Rule of 40 score: 0
Financial ratios for BRO.V — annual report dated 2024-03-31
Total revenue: 0
Gross profit: -19907.407407407405
Operating income: -2118188.8888888885
Net income: -3426851.111111111
Capital expenditures: 4567917.037037036
Operating cash flow: -1010418.5185185184
Depreciation & amortization: 19907.407407407405
Net tangible assets: 15722122.962962963
Owner earnings: -7974860.740740741
Return on net tangible assets (%): -50.723816112667095
Buffett classification: The Gruesome
Stock price: 0.10294117647058824
Shares outstanding: 206097077
Book value: 15722122.96296296
P/B ratio: 1.3494281671443633
Market cap (USD): 21215875.573529415
Debt to equity: 0.06938258173220034
Current ratio: 0.6463055053065735
Quick ratio: 0.6463055053065735
Interest coverage ratio: -17.386589570070953
Free cash flow (dilution-adjusted): -6309000.740740741
Buyback yield (%): 0
Retained earnings: -24730168.148148146
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -13.45719170587978
Rule of 40 score: 0
Financial ratios for BRO.V — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 0.1259259259259259
Shares outstanding: 206097077
Market cap (USD): 25952965.25185185
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for BRO.V — quarterly report dated 2024-12-31
Total revenue: 0
Gross profit: 0
Operating income: -350641.25874125876
Net income: -355251.7482517483
Capital expenditures: 0
Operating cash flow: -1044353.1468531468
Depreciation & amortization: 0
Net tangible assets: 18046088.811188813
Owner earnings: -355251.7482517483
Return on net tangible assets (%): -1.9685802944263884
Buffett classification: The Gruesome
Stock price: 0.1188811188811189
Shares outstanding: 206097077
Book value: 18046088.81118881
P/B ratio: 1.3576931471542544
Market cap (USD): 24501051.111888114
Debt to equity: 0.06564768291228827
Current ratio: 0.441749841454368
Quick ratio: 0.441749841454368
Interest coverage ratio: -13.26219318662717
Free cash flow (dilution-adjusted): -1127269.9300699302
Buyback yield (%): 0
Retained earnings: -24391573.42657343
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -1.9430318802590434
Rule of 40 score: 0
Financial ratios for BRO.V — quarterly report dated 2025-03-31
Total revenue: 0
Gross profit: -9396.503496503497
Operating income: -313896.5034965035
Net income: -1529132.1678321678
Capital expenditures: 0
Operating cash flow: 927321.6783216783
Depreciation & amortization: 9396.503496503497
Net tangible assets: 16882360.139860142
Owner earnings: -1519735.6643356644
Return on net tangible assets (%): -9.001914730793406
Buffett classification: The Gruesome
Stock price: 0.08391608391608392
Shares outstanding: 206097077
Book value: 16882360.139860142
P/B ratio: 1.0244337560100696
Market cap (USD): 17294859.60839161
Debt to equity: 0.05973935222244428
Current ratio: 0.08664626512727779
Quick ratio: 0.08664626512727779
Interest coverage ratio: -11.760119468678772
Free cash flow (dilution-adjusted): -3621037.7622377626
Buyback yield (%): 0
Retained earnings: -25763130.76923077
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -1.859316475279883
Rule of 40 score: 0
Financial ratios for BRO.V — annual report dated 2025-03-31
Total revenue: 0
Gross profit: -18793.706293706295
Operating income: -1415603.4965034965
Net income: -2801204.195804196
Capital expenditures: 4491213.986013986
Operating cash flow: -828914.6853146853
Depreciation & amortization: 18793.706293706295
Net tangible assets: 16882360.139860142
Owner earnings: -7273624.475524476
Return on net tangible assets (%): -43.08416841760806
Buffett classification: The Gruesome
Stock price: 0.08391608391608392
Shares outstanding: 206097077
Book value: 16882360.139860142
P/B ratio: 1.0244337560100696
Market cap (USD): 17294859.60839161
Debt to equity: 0.05973935222244428
Current ratio: 0.08664626512727779
Quick ratio: 0.08664626512727779
Interest coverage ratio: -13.239024230731498
Free cash flow (dilution-adjusted): -5643704.895104895
Buyback yield (%): 0
Retained earnings: -25763130.76923077
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -8.38510424357778
Rule of 40 score: 0
Financial ratios for BRO.V — quarterly report dated 2025-06-30
Total revenue: 0
Gross profit: -4904.379562043795
Operating income: -272241.60583941604
Net income: -782954.01459854
Capital expenditures: 677712.408759124
Operating cash flow: -199364.96350364963
Depreciation & amortization: 4904.379562043795
Net tangible assets: 17633395.620437954
Owner earnings: -1455762.04379562
Return on net tangible assets (%): -8.255710216745332
Buffett classification: The Gruesome
Stock price: 0.0875912408759124
Shares outstanding: 206097077
Book value: 17633395.620437957
P/B ratio: 1.0237562352655991
Market cap (USD): 18052298.715328466
Debt to equity: 0.14654819703422733
Current ratio: 4.4440345788053275
Quick ratio: 4.4440345788053275
Interest coverage ratio: -4.239752188245993
Free cash flow (dilution-adjusted): -942418.9781021897
Buyback yield (%): 0
Retained earnings: -27674397.080291968
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -1.3473677107157946
Rule of 40 score: 0